January 2021Automation...FY 2022 Brooks Target Model - Revised • Revenue range $580 - 680M •...

January 2021

Brooks Automation

Investor Overview

Safe Harbor Statement

2

“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this

presentation, including forecasts of future demand and future Company performance, are forward-looking

statements that are subject to risks and uncertainties that could cause actual results to materially differ, either

better or worse, from those projected. Further discussions of risk factors are available in the Company’s most

recent SEC filings, including the annual report on Form 10-K for the fiscal year ended September 30, 2020 and

any subsequent quarterly reports on Form 10-Q. The Company assumes no obligation to update the

information in this presentation.

Regulation G

This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the

Brooks business and its operational performance. These measures should always be considered in

conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant

GAAP amount are provided as a separate presentation on the Company’s website. All financial projections

throughout this presentation, other than ROIC, exclude amortization of intangibles, restructuring expense and

other special charges.

© 2021 Brooks Automation, Inc. • Proprietary Information

Driving Performance. Delivering Profitable Growth.

• Brooks overview

• Building on two strong platforms – Life Sciences and Semiconductor

• Model for profitable growth

3© 2021 Brooks Automation, Inc. • Proprietary Information

Brooks at a Glance: Serving Global Life Sciences and Semiconductor Markets

Semiconductor

SolutionsLife Sciences

✓ Wafer Automation

✓ Contamination Control

✓ Global Service Support

✓ Sample Management

Products and Services

✓ Genomic Services

FY’20 $897M (+15% YtY)

~ 3,200 Global Employees

Sales in 50 Countries

NASDAQ: BRKS

Sept 30 Year-End

Annual Dividend

$0.40/share


Accelerating a Strong Track Record of Growth and Margin Expansion

* Non-GAAP financial measure – see Regulation G statement on pg.2

$434

$632

2016 2018 2020

$0.21

$0.64

$1.26

2016 2018 2020

$M

37%

40%

44%

2016 2018 2020

20%CAGR >6 pts 57%

CAGR

Revenue EPS*Gross Margin*

$897


Transformation to Higher Growth, Higher Margin Profile

17%

83%

$407M

2015

43%

57%$897M

2020

Life Sciences

Semiconductor

$632M

2018

31%

69%



• Brooks overview




$108

$149

$197

$334

$389

FY'16 FY'17 FY'18 FY'19 FY'20

Building on Two Strong PlatformsLife Sciences

8

What We Do

Products - Sample Storage

Infrastructure, Consumables

and Instruments

Services – Genomics and

Sample Storage Services

Revenue

+38%

CAGR

Our Value

Best-in-Class Solutions

✓ Science

✓ Technology

Quality & Integrity

✓ Sample assets

✓ Expert analysis

Efficiency in Workflow

✓ Fast Turnaround Time

✓ Capital

+16%

YtY


16%

12%

15%24%

19%

9%5%

Life Sciences – Diverse Revenue ProfileAligned for Higher Growth

Ultra-Cold Automated

Stores

Sample & Repository Solutions

Service

Consumables&

Instruments

Next Gen Sequencing

SangerSequencing

Gene Synthesis &

Other

Serving a $10B Market in

Sample Storage and

Genomics

• Discovery research

• Drug and biological drug

development

• Clinical research and trials

• Precision medicine

• Regenerative medicine

• Cell and gene therapy

• Agriculture

Products

33%Services

67%


Our Expertise has Allowed Us to Win an Impressive Global Customer Base

Leading healthcare institutions depend on Brooks

Healthcare / Clinical Academic / GovtPharma / Biotech



• Brooks overview




$326

$379

$435 $447

$509

FY'16 FY'17 FY'18 FY'19 FY'20

Building on Two Strong Platforms Semiconductor Solutions

12

What We Do

Wafer Level Automation

- Robotics and Systems

Contamination Control

- Carrier cleaning

- Reticle Stockers

Global Service and Support

+14%

YtY

Our Value

Enabling Process

Advantages

✓ Precision handling

✓ Productivity

✓ Reliability

✓ Process control

✓ Yield Enhancement

✓ Trusted partner

Revenue

+12%

CAGR


Market Drivers of Wafer Fab Equip. CAPEX

Enabling CustomerProcess Advantages

All Wafer Fabs

All Technology Nodes

Logic, Foundry & Memory

Brooks Leads in Automation, Vacuum Environments, and

Contamination Control

Vacuum Automation Systems & Robots

Carrier Cleaners & Reticle Stockers

Advanced Packaging Solutions

#1

#1

#1

Volume Demand

• New chip factory lines

• Capacity build-out

Chip Complexity

Leading edge technology drives:

• More process steps

• Contamination vulnerability

Semiconductor Equipment CAPEX Market Growth Driven by New Applications and Manufacturing Complexity

Glo

bal S

erv

ice


http://www.google.com/url?url=http://www.brooks.com/products/semiconductor-automation/alignment-calibration-tools/interface-adapters/wafers-adapters-in-foup/150mm&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwjcuMndrM3MAhWGFj4KHY5FAB0QwW4IGjAC&sig2=IPxx3cQcF6PGV1D4hoYdlA&usg=AFQjCNFzraKDsmNCiUgF5Cck5iNREwiKKw

Device Manufacturers

~40%*Equipment Manufacturers

~60%*

Leading Customers in High-Growth Segments

Contamination Control Advanced PackagingVacuum Automation

100%

14© 2021 Brooks Automation, Inc. • Proprietary Information * Estimated FY2020 revenue % based on management’s internal estimates.


• Brooks overview




Consistent Strategy Going Forward

Extend leadership in core markets1Advance the rapid growth of Life Sciences

with organic and acquisition investments2Drive margin expansion3Utilize balanced and disciplined

capital deployment4


Life Sciences Semiconductor

FY 2022 Brooks Target Model - Revised

• Revenue range $580 - 680M

• CAGR from 2020 ~11%

• Gross Margin* target 42-44%

• OPEX productivity

• Revenue growth $520M

• CAGR from 2020 16%

• Gross Margin* target 48-51%

• OPEX productivity

20-22%Operating Margins*

55%% of Brooks revenue

16-20%Operating Margins*

45%% of Brooks revenue

Revenue CAGR

from 2020

13%

ROIC of

13%

Operating

Margins*

19%

Brooks

* Non-GAAP financial measure 17© 2021 Brooks Automation, Inc. • Proprietary Information

FY 2022 Target Model - Revised

FY 2016 FY 2018 FY 2020

Total RevenueSemi

Life Sciences

% of total

$434M $326M

$108M

25%

$632M $435M

$197M

31%

$897M $509M

$389M

43%

Gross Margin* 37.2% 40.0% 43.6%

Operating Expenses*

% of Revenue34.2% 29.7% 30.0%

Operating Income*

% of Revenue

$13M

2.9%

$65M

10.3%

$122M

13.6%

EBITDA*

EPS*

$34M

$0.21

$93M

$0.64

$161M

$1.26

FY 2022 Goal

$1,100-1,200M$580-680M

$520M

~45%

45-47%

27-28%

$200-240M

18%-20%

$245-285M

$2.00-2.40

* Non-GAAP financial measure 18© 2021 Brooks Automation, Inc. • Proprietary Information

• Priority in Life Sciences and opportunistic in Semi

• ROIC focus

Disciplined Capital Deployment Over Last 5 YearsStrong Cash Generation Affords Investment

~59%M&A

Return Cash to Shareholders• Dividends – $142M cumulative

on $0.40 per share annually

CAPEX

~8%

~12%

Organic Growth• Investment of ~$50M

in R&D annually

~21%

$1.2B

Deployed

• Low CAPEX operations- 2-3% of revenue historically- Expect 4-6% of revenue with GENEWIZ

Last 5 years = FY2016 - FY2020 19© 2021 Brooks Automation, Inc. • Proprietary Information

• GENEWIZ for

$450M

• RURO for $15M

• Divested Semi Cryo

for $675M

Continuous Portfolio Enhancement for Value and Higher Growth

• RTS for $3M

• Nexus for $85M

• Crossing

Automation

for $59M

• Divested of

Contract

Manufacturing

for $78M

• Matrical for $9M

• 22% of BioCision

for $4M

• DMS for $32M

• Divested of

Granville-Phillips

instrumentation

for $87M

• FluidX for

$16M

• BioStorage

Technologies

for $125M

• Contact for $7M

2013-2014

2015-2016

• BioCision add’l $11M

• PBMMI for $34M

• FreezerPro software for $5M

• 4titude Ltd. for $66M

• BioSpeciMan for $5M

• Tec-Sem for $16M

2017-2018

Acquisitions

Life Sciences >$800M

Semi >$100M

2019 - 2020

10 years, 21 transactions, with ROIC focus

2011-2012


• Trans-Hit

Biomarkers

FY2021

http://www.google.co.uk/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0CAMQjRxqFQoTCP63_-XNl8gCFULOgAodwBgL7A&url=http://chinesebrains.com/2013/10/11/biostorage-technologies-announces-growth-china/&psig=AFQjCNF02aCF8w50uJMWKG6waiWKV4f3qg&ust=1443456813106930

$M except EPS Q1’20 Q2’20 Q3’20 Q4’20 Guidance for

Q1’21Ending 12/31/20

Brooks Total Revenue

Semiconductor Solutions

Life Science

$210$119

$92

$220$125

$95

$220$127

$93

$246$138

$108

$237-251$132-140

$105-111

Adjusted EBITDA* $32 $35 $40 $54 $46-56

Non-GAAP EPS* $0.23 $0.25 $0.32 $0.47 $0.37-$0.47

Dividends/share Returned

to Shareholders$0.10 $0.10 $0.10 $0.10 $0.10**

Guidance As Provided November 10, 2020Continuing Operations

** The Board of Directors approved a dividend of $0.10 per share, which was paid on December 17, 2020 to stockholders of record on December 4, 2020

© 2021 Brooks Automation, Inc. • Proprietary Information 21* Non-GAAP financial measure

Two Strong Markets with Strong Leadership Positions

Attractive Long TermFinancial Model

Track Record of Effective Capital Deployment

I N S U M M A R Y

Two High Performance Businesses. Positioned for Profitable Growth and Further Investment

✓ Semiconductor

Equipment and Service

✓ Life Sciences Sample

Management and

Genomics

✓ Two profitable growth

businesses

✓ ROIC Focused

✓ Capturing opportunity

for growth & value

through acquisitions

✓ 10th year of dividends

✓ Significant operating

leverage for increased

profits & cash

Strong Performance in a Challenging Market Environment

✓ Momentum for incremental growth and

margin expansion

✓ Operating leverage drives EPS growth

22

$434

$632

2016 2018 2020

…

$0.64

$1.26

2016 2018 2020

Revenue EPS*$897

$0.21

$ millions except EPS

* Non-GAAP financial measure© 2021 Brooks Automation, Inc. • Proprietary Information

Thank You

23

Non-GAAP Reconciliation Appendix

24

Non-GAAP Annual Operating PerformanceContinuing Operations

* Non-GAAP financial measure

$ millions, except EPS

25

FY16 FY17 FY18 FY19 FY20

Revenue 434 527 632 781 897

Gross profit* 161 203 253 327 391

Gross profit margin* 37.2 % 38.5 % 40.0 % 41.9 % 43.6 %

R&D expenses 44 40 47 56 59 SG&A expenses* 104 120 141 181 210

Operating income * 13 43 65 90 122

Operating margin* 2.9 % 8.2 % 10.3 % 11.6 % 13.6 %

Other income (expense)* (1) (2) (11) (22) (3) Tax benefit (provision)* 4 (10) (9) (13) (26) JV and noncontrolling interests* (1) (0) - - -

Net income* 15 31 45 55 93

Net income margin* 3.4 % 5.9 % 7.2 % 7.1 % 10.4 %

Diluted Non-GAAP EPS - Continuing Ops* 0.21 0.44 0.64 0.76 1.26

Adjusted EBITDA* 34 68 93 128 161


Total Brooks

Non-GAAP Annual Operating Performance – Business SegmentsContinuing Operations

$ millions


FY18 FY19 FY20

Revenue 435 447 509

Gross profit* 178 185 211

Gross profit margin* 40.9 % 41.5 % 41.4 %

Operating expenses 116 115 128

Operating income * 63 70 83

Operating margin* 14.4 % 15.7 % 16.3 %

FY18 FY19 FY20

Revenue 197 334 389

Gross profit* 75 142 181

Gross profit margin* 38.0 % 42.4 % 46.5 %

Operating expenses 71 121 142

Operating income * 4 21 38

Operating margin* 1.9 % 6.2 % 9.8 %

Brooks Life Sciences

Brooks Semiconductor Solutions


Non-GAAP Quarterly Operating PerformanceContinuing Operations



27

Q4'19 Q1'20 Q2'20 Q3'20 Q4'20

Revenue 199 210 220 220 246

Gross profit* 83 88 93 96 115


R&D expenses 15 14 15 14 15 SG&A expenses* 47 51 52 52 55



Other income (expense) (1) (0) (2) (0) (1) Tax benefit (provision)* (4) (5) (5) (6) (10)

Net income* 17 17 18 23 35

Net income margin* 8.5 % 7.9 % 8.4 % 10.6 % 14.0 %

Diluted Non-GAAP EPS - Continuing Ops* 0.23 0.23 0.25 0.32 0.47

Adjusted EBITDA* 31 32 35 40 54

Total Brooks


Non-GAAP Quarterly Operating Performance – Business SegmentsContinuing Operations


$ millions

28

Q4'19 Q1'20 Q2'20 Q3'20 Q4'20

Revenue 105 119 125 127 138

Gross profit* 43 47 49 54 60


Operating expenses 30 32 33 31 32



Q4'19 Q1'20 Q2'20 Q3'20 Q4'20

Revenue 94 92 95 93 108

Gross profit* 40 41 44 42 55


Operating expenses 33 35 36 35 37



Brooks Semiconductor Solutions

Brooks Life Sciences


GAAP to Non-GAAP ReconciliationFY2016 - FY2020 Total Brooks – Continuing Operations


29

FY 2016 FY 2017 FY 2018 FY 2019 FY 2020

Revenue 434 527 632 781 897

GAAP gross profit 157 199 246 316 380

Merger and acquisition costs 1 1 2 0 -

Amortization expense 4 4 5 10 11

Other Special Charges - - - 0 0

Non-GAAP gross profit 161 203 253 327 391

Gross profit margin 36% 38% 39% 41% 42%

Non-GAAP gross profit margin 37% 39% 40% 42% 44%

GAAP operating expenses (174) (185) (215) (270) (302)

Merger and acquisition costs 3 8 7 7 1


Restructuring and related charges 10 3 1 2 1

Other Special Charges 1 - - - -

Non-GAAP operating expenses (149) (160) (188) (237) (269)

GAAP operating profit (loss) (17) 14 31 46 78

Non-GAAP operating profit (loss) 13 43 65 90 122

Operating profit margin -4% 3% 5% 6% 9%

Non-GAAP operating profit margin 3% 8% 10% 12% 14%

GAAP net income (loss) (85) 11 68 10 65




Other Special Charges 1 (1) (0) - -

Loss on extinguishment of debt - - - 14 -

Tax related adjustments 77 (4) (44) 2 (4)

Tax effect of adjustments (6) (3) (13) (14) (13)

Non-GAAP net income 15 31 45 55 93

Diluted earnings per share (1.25) 0.15 0.95 0.13 0.88

Non-GAAP diluted earnings per share 0.21 0.44 0.64 0.76 1.26


GAAP to Non-GAAP ReconciliationFY2018 - FY2020 Business Segments – Continuing Operations

$ millions

30

FY 2018 FY 2019 FY 2020


Revenue 435$ 447$ 509$

GAAP gross profit 174 182 208

Merger and acquisition costs 1 - -

Amortization expense 3 4 3

Non-GAAP gross profit 178 185 211

Gross profit margin 40% 41% 41%

Non-GAAP gross profit margin 41% 41% 41%

Operating expenses (116) (115) (128)

GAAP operating profit 58 66 80

Non-GAAP operating profit 63 70 83

Operating profit margin 13% 15% 16%

Non-GAAP operating profit margin 14% 16% 16%

FY 2018 FY 2019 FY 2020

Life Sciences

Revenue 197$ 334$ 389$

Gross profit 72 135 172



Other special charges - - -





Operating profit 1 14 30




GAAP to Non-GAAP ReconciliationFY2018 - FY2020 Segments – Continuing Operations

$ millions

31

FY 2018 FY 2019 FY 2020

Life Science Products

Revenue 106$ 119$ 130$









GAAP operating profit (loss) (12) (3) 8

Non-GAAP operating profit (loss) (9) (2) 9

Operating profit margin -11% -3% 6%

Non-GAAP operating profit margin -9% -2% 7%

FY 2018 FY 2019 FY 2020

Life Science Services

Revenue 90$ 215$ 259$


Merger and acquisition costs - - -

Amortization expense - 6 7






GAAP operating profit 13 17 22



Non-GAAP operating profit margin 14% 10% 11%


GAAP to Non-GAAP ReconciliationQ4’19 – Q4’20 Total Brooks – Continuing Operations


32

Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20

Revenue 199 210 220 220 246


Merger and acquisition costs - - - - -


Restructuring and related charges 0 - - 0 -




GAAP operating expenses (70) (74) (76) (74) (78)



Restructuring and related charges 1 1 1 (0) 0

Non-GAAP operating expenses (62) (66) (67) (66) (70)

GAAP operating profit 11 11 15 19 34

Non-GAAP operating profit 21 22 26 30 45

Operating profit margin 5% 5% 7% 9% 14%


GAAP net income 5 13 9 14 29




Loss on extinguishment of debt 5 - - - -

Tax related adjustments (0) (5) 1 2 (1)

Tax effect of adjustments (4) (3) (3) (3) (4)

Non-GAAP net income 17 17 18 23 35

Diluted earnings per share 0.07 0.18 0.12 0.19 0.39

Non-GAAP diluted earnings per share 0.23 0.23 0.25 0.32 0.47


GAAP to Non-GAAP ReconciliationQ4’19 – Q4’20 Business Segments – Continuing Operations

$ millions

33



Revenue 105$ 119$ 125$ 127$ 138$






Operating expenses (30) (32) (33) (31) (32)





Life Sciences

Revenue 94$ 92$ 95$ 93$ 108$

Gross profit 38 39 42 39 53


Other special charges 0 - - 0 -





Operating profit 5 4 6 4 15





GAAP to Non-GAAP ReconciliationQ4’19 – Q4’20 Segments – Continuing Operations

$ millions

34


Life Sciences Products

Revenue 32$ 30$ 31$ 30$ 39$



Other special charges - - - - -










Life Sciences Services

Revenue 62$ 62$ 64$ 63$ 70$



Other special charges 0 - - 0 -










Net Income Reconciliation to Adjusted EBITDAFY2016 to FY2020 – Continuing Operations

$ millions

35

FY'16 FY'17 FY'18 FY'19 FY'20

Net income (loss) attributable to Brooks Automation, Inc. (69.5) 62.6 116.6 437.4 64.9

Income from discontinued operations, net of tax (16.0) (51.9) (48.7) (427.9) 0.2

Net income (loss) from continuing operations (85.5) 10.7 67.8 9.6 65.0

Adjustments:

Interest income (0.5) (0.5) (1.9) (1.4) (0.8)

Interest expense 0.2 0.4 9.5 22.2 2.9

Income tax provision (benefit) 66.3 3.4 (47.3) (0.1) 9.9

Depreciation 12.2 10.4 12.5 19.3 23.7

Amortization of intangible assets 14.8 17.1 24.2 35.2 41.8

Loss on extinguishment of debt - - - 14.3 -

EBITDA-from Continuing Operations 7.5 41.5 64.9 99.0 142.6

Non-GAAP adjustments:

Purchase accounting impact on inventory

and contracts acquired 0.6 0.5 1.9 0.2 (0.0)

Stock-based compensation 11.3 16.6 18.9 19.5 16.3

Restructuring 10.2 3.1 0.7 1.9 1.4

Restructuring related charges - - - 0.3 0.3

Merger and acquisition costs / Other 4.2 6.7 6.9 6.7 0.5

Adjusted EBITDA - from Continuing Operations 33.8 68.5 93.3 127.6 161.0


Total Brooks

Net Income Reconciliation to Adjusted EBITDAQ4’19 – Q4’20 – Continuing Operations

$ millions

36

Q4'19 Q1'20 Q2'20 Q3'20 Q4'20

Net income attributable to Brooks Automation, Inc. 412.3 13.1 9.1 13.7 29.0

(Income) loss from discontinued operations, net of tax (407.1) 0.1 0.1 - 0.0

Net income from continuing operations 5.2 13.2 9.2 13.7 29.0

Adjustments:

Interest income (0.6) (0.7) (0.1) (0.0) 0.0

Interest expense 0.9 0.7 0.7 0.8 0.7

Income tax provision (benefit) (0.5) (3.0) 3.4 5.1 4.4

Depreciation 5.1 5.9 6.2 6.3 5.3

Amortization of intangible assets 8.9 10.6 10.4 10.4 10.4

Loss on extinguishment of debt 5.3 - - - -

EBITDA-from Continuing Operations 24.3 26.7 29.8 36.3 49.8

Non-GAAP adjustments:

Stock-based compensation 4.9 4.4 4.2 3.7 4.0

Restructuring charges 1.2 0.6 0.6 (0.0) 0.2

Restructuring related charges 0.3 - - 0.3 -

Merger and acquisition costs / Other 0.1 0.2 0.3 0.0 0.0

Adjusted EBITDA - from Continuing Operations 30.9 31.9 34.8 40.3 54.0


Total Brooks

January 2021Automation...FY 2022 Brooks Target Model - Revised • Revenue range $580 - 680M •...

Documents

Transcript of January 2021Automation...FY 2022 Brooks Target Model - Revised • Revenue range $580 - 680M •...